AJCN North Carolina Research Campus
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
QUICK SEARCH:   [advanced]


     

This Article
Right arrow Full Text (PDF)
Right arrow Purchase Article
Right arrow View Shopping Cart
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by LERNER, L. J.
Right arrow Articles by MICHEL, I.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by LERNER, L. J.
Right arrow Articles by MICHEL, I.
Agricola
Right arrow Articles by LERNER, L. J.
Right arrow Articles by MICHEL, I.

American Journal of Clinical Nutrition, Vol 23, 1241-1250, Copyright © 1970 by The American Society for Clinical Nutrition, Inc.

Cholesterol Synthesis Inhibitor Showing Reduction of Lipids and Hormone Antagonism

LEONARD J. LERNER PH.D.1, DON N. HARRIS PH.D.1, EURIPIDES YIACAS M.S.1, RUSSELL HILF PH.D.1, and INGE MICHEL B.S.1

1 From the Squibb Institute for Medical Research, New Brunswick, N.J.

The compound, SQ 10,591, lowered plasma cholesterol in rats fed normal or hyperlipemic diets by blocking the biosynthesis of cholesterol between mevalonate and lanosterol. It also reduced serum free fatty acids and triglycerides. In addition to its effect on lipids, SQ 10,591 inhibited the uterotrophic activity of estrogen in mice and inhibited production or release of pituitary gonadotrophins in rats. In mature female rats SQ 10,591 caused an interruption of the estrous cycle.






HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Copyright © 1970 by The American Society for Nutrition